Physician profile
Suzanne Ayers Iodice
NPI 1013069020
$1,038.44
in general payments reported to CMS, 2019-2025
15 companies · $34.28 in 2025
The $34.28 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $118 · 2021: $194 · 2022: $185 · 2023: $48.81 · 2024: $243 · 2025: $34.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $367.75 | 2019-2023 | |
| Lexicon Pharmaceuticals, INC. | $143.18 | 2024 | |
| Vifor Pharma, INC. | $109.66 | 2019-2022 | |
| Abbvie INC. | $73.62 | 2021-2024 | |
| Melinta Therapeutics, LLC | $68.30 | 2022-2024 | Rezzayo, Kimyrsa |
| Novartis Pharmaceuticals Corporation | $54.23 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $44.78 | 2019-2022 | |
| Viatris Specialty LLC | $34.28 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $30.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.77 | 2019-2022 | |
| Biofire Diagnostics, LLC | $22.20 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $21.04 | 2024 | Arcalyst |
| Nabriva Therapeutics, Plc | $14.62 | 2020 | |
| Gilead Sciences, INC. | $14.62 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Iodice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.